Gupta Sanjana, Pepper Ruth J, Ashman Neil, Walsh Stephen B
UCL Centre for Nephrology, University College London, London, United Kingdom.
Renal Unit, The Royal London Hospital, Bart's Health NHS Trust, London, United Kingdom.
Front Physiol. 2019 Jan 15;9:1868. doi: 10.3389/fphys.2018.01868. eCollection 2018.
Oedema is a defining element of the nephrotic syndrome. Its' management varies considerably between clinicians, with no national or international clinical guidelines, and hence variable outcomes. Oedema may have serious sequelae such as immobility, skin breakdown and local or systemic infection. Treatment of nephrotic oedema is often of limited efficacy, with frequent side-effects and interactions with other pharmacotherapy. Here, we describe the current paradigms of oedema in nephrosis, including insights into emerging mechanisms such as the role of the abnormal activation of the epithelial sodium channel in the collecting duct. We then discuss the physiological basis for traditional and novel therapies for the treatment of nephrotic oedema. Despite being the cardinal symptom of nephrosis, few clinical studies guide clinicians to the rational use of therapy. This is reflected in the scarcity of publications in this field; it is time to undertake new clinical trials to direct clinical practice.
水肿是肾病综合征的一个决定性要素。临床医生对其处理方法差异很大,目前尚无国家或国际临床指南,因此治疗结果也各不相同。水肿可能会引发严重的后遗症,如活动受限、皮肤破损以及局部或全身感染。肾病性水肿的治疗效果往往有限,且经常出现副作用,还会与其他药物治疗产生相互作用。在此,我们描述了当前肾病中水肿的范式,包括对一些新出现机制的见解,如集合管上皮钠通道异常激活所起的作用。然后我们讨论了治疗肾病性水肿的传统疗法和新疗法的生理基础。尽管水肿是肾病的主要症状,但很少有临床研究指导临床医生合理使用治疗方法。这反映在该领域的出版物较少;现在是时候开展新的临床试验来指导临床实践了。